ライフサイエンスコーパス: plasma cell dyscrasia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 f progression to multiple myeloma or another plasma cell dyscrasia.

2 l for following patients with oligosecretory plasma cell dyscrasia.

3 plantation after relapse of their underlying plasma cell dyscrasia.

4 stemic disorder resulting from an underlying plasma cell dyscrasia.

5 ents achieving eradication of the underlying plasma cell dyscrasia.

6 changes) is a rare disease associated with a plasma cell dyscrasia.

7 t a role for nontreatment-related factors in plasma cell dyscrasias.

8 proximal tubule epithelium, particularly in plasma cell dyscrasias.

9 in levels that are seen in patients who have plasma cell dyscrasias.

10 nal involvement is a frequent consequence of plasma cell dyscrasias.

11 ide insight into the molecular mechanisms of plasma-cell dyscrasias.

12 nse, defined as no evidence of an underlying plasma cell dyscrasia 1 year after treatment, was achiev

13 eased incidence of monoclonal gammopathy and plasma cell dyscrasias.2,3 The exact mechanism of monocl

14 noglobulin light chains produced by a clonal plasma cell dyscrasia accumulate in tissues and damage v

15 1 identifies healthy individuals at risk for plasma cell dyscrasias and that dominant inheritance of

16 Plasma cell dyscrasias appear to have a modestly increas

17 the patterns of gene methylated for L/L and plasma cell dyscrasias are different.

18 Plasma cell dyscrasias are frequently encountered malign

19 Plasma cell dyscrasias are frequently encountered malign

20 Primary (AL) amyloidosis is a plasma cell dyscrasia characterized by clonal production

21 Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the presence of m

22 assessable patients with heavily pretreated plasma cell dyscrasias completing one cycle of therapy,

23 patients (60%) at 12 months after treatment, plasma cell dyscrasias could not be detected.

24 loidosis achieve complete remission of their plasma cell dyscrasia, improvement in performance status

25 ell transplantation induces remission of the plasma cell dyscrasia in a substantial proportion of pat

26 Thus, aggressive treatment of the underlying plasma cell dyscrasia in AL amyloidosis can lead to the

27 Light chain-associated amyloidosis (AL) is a plasma cell dyscrasia in which the secreted monoclonal i

28 Plasma cell dyscrasias, including monoclonal gammopathy

29 opathy of undetermined significance or other plasma cell dyscrasias involving the bone marrow, expres

30 yloidosis and not the result of a monoclonal plasma cell dyscrasia, may be misdiagnosed and lead to i

31 ic bone diseases in malignancies such as the plasma cell dyscrasia multiple myeloma (MM) is not known

32 e useful in differentiating POEMS from other plasma cell dyscrasias, neuropathic processes, and multi

33 POEMS syndrome is a rare plasma cell dyscrasia presenting with polyneuropathy and

34 ding of the pathophysiology and diagnosis of plasma cell dyscrasia related kidney diseases.

35 a continues to expand, but the cause of this plasma cell dyscrasia remains unclear.

36 Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure a

37 In the setting of a plasma cell dyscrasia, significant amounts of free light

38 hey are also largely present in premalignant plasma cell dyscrasia such as monoclonal gammopathy of u

39 nsight into the molecular defects underlying plasma cell dyscrasias that may explain their clinical h

40 renal cell carcinoma, malignant melanoma, or plasma cell dyscrasia, we related responses to questionn

41 Their plasma cell dyscrasias were evaluated with immunofixatio

42 Well-selected patients with plasma cell dyscrasias whose monoclonal Ig is well contr

43 ring multiple myeloma (SMM) are asymptomatic plasma cell dyscrasias, with a propensity to progress to

44 Four families had two or more members with plasma cell dyscrasias, with or without a single case of

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。